NCT06617546View on ClinicalTrials.gov

SAD and MAD Study of FTX-101 in Healthy Male Subjects

PHASE1TerminatedINTERVENTIONAL

Enrollment

49

Participants

Timeline

Start Date

October 14, 2024

Primary Completion Date

April 17, 2025

Study Completion Date

April 17, 2025

Conditions

Healthy Volunteers

Interventions

DRUG

FTX-101

Lyophilized powder for subcutaneous injection

DRUG

Placebo

Lyophilized powder for subcutaneous injection

Trial Locations (1)

66212

Altasciences Clinical Kansas, Inc., Overland Park

Sponsors

Lead Sponsor

Find Therapeutics

All Listed Sponsors

lead

Find Therapeutics

INDUSTRY